Vivos Inc. (RDGL)
OTCMKTS · Delayed Price · Currency is USD
0.0700
+0.0011 (1.60%)
Jan 20, 2026, 4:00 PM EST
Vivos Revenue
Vivos had revenue of $1.88K in the quarter ending September 30, 2025, a decrease of -62.42%. This brings the company's revenue in the last twelve months to $48.62K, up 111.40% year-over-year. In the year 2024, Vivos had annual revenue of $28.00K with 43.56% growth.
Revenue (ttm)
48.62K
Revenue Growth
+111.40%
P/S Ratio
645.46
Revenue / Employee
48.62K
Employees
1
Market Cap
31.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.00K | 8.50K | 43.56% |
| Dec 31, 2023 | 19.50K | -17.00K | -46.57% |
| Dec 31, 2022 | 36.50K | 21.61K | 145.17% |
| Dec 31, 2021 | 14.89K | 7.89K | 112.67% |
| Dec 31, 2020 | 7.00K | -2.50K | -26.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
Vivos News
- 4 weeks ago - Vivos Inc Summarizes Progress in its Animal Therapy Division - GlobeNewsWire
- 4 weeks ago - Vivos Inc Summarzes Preogress in its Animal Therapy Division - GlobeNewsWire
- 2 months ago - Vivos Inc. Issues Shareholder Update Letter - GlobeNewsWire
- 2 months ago - Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics - GlobeNewsWire
- 3 months ago - Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D. - GlobeNewsWire
- 4 months ago - Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India - GlobeNewsWire
- 4 months ago - Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India - GlobeNewsWire
- 4 months ago - Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy - GlobeNewsWire